RFA-IP-23-006: Developing a Public Health Tool to Predict the Virality of Vaccine Misinformation Narratives
Closed
This grant is closed. A newer notice from the same program is forecast: Informing global polio eradication efforts through innovative modeling approaches (CDC-RFA-JG-27-0077). Status: Expected deadline February 12, 2027. It is in our archive of Centers for Disease Control and Prevention - ERA notices from 2022.
Centers for Disease Control and Prevention - ERA offered grants of up to $500,000 (at least $400,000) to nonprofits, colleges and universities, state and local governments and tribes. It expected to make one award worth $1.0 million in total. Applications closed on January 6, 2023.
From the official notice on Grants.gov, last changed October 20, 2022. Checked November 7, 2026.
- Award ceiling$500,000
- Award floor$400,000
- Total funding$1.0 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | October 20, 2022 |
|---|---|
| Deadline | January 6, 2023 |
| Archived by Grants.gov | March 10, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments and tribes.
All 12 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Non-profit private institutions of higher education Nonprofits (Other than Institutions of Higher Education)The following types of Higher Education Institutions are always encouraged to apply for CDC support as Non-profit Public or Non-profit Private Institutions of Higher Education: Hispanic-serving Institutions Historically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) Alaska Native and Native Hawaiian Serving Institutions
Is this a realistic fit?
- Past Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects awards averaged $3.5 million; this notice allows up to $500,000 per award.
- Most of the program's money (47% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
The purpose of this Notice of Funding Opportunity is to support research to develop a predictive forecasting model that identifies new or reemerging misinformation narratives that are likely to disseminate widely and have a high potential for impact on vaccine confidence. The information from this model will then be used to develop a tool that public health agencies could use to predict misinformation trends in the populations served. Finally, the researchers will evaluate the tool's predictive capabilities on both future social media misinformation narratives and real-world events.
Who has won Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects grants before
From fiscal 2021 to 2025, Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects (93.185) awarded $857 million across 243 grant awards, an average of $3.5 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Unicef | New York | 2 | $133 million |
| National Foundation for the Centers for Disease Control & Prevention, Inc. | Georgia | 2 | $74.7 million |
| Community Catalyst Inc | Massachusetts | 1 | $39.4 million |
| Pan American Health Organization | District of Columbia | 3 | $21.9 million |
| Unidosus | District of Columbia | 1 | $18.6 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-JG-27-0077, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-IP-23-006 still open?
No. It closed on January 6, 2023. A newer notice is forecast: CDC-RFA-JG-27-0077, expected deadline February 12, 2027.
Who can apply for Developing a Public Health Tool to Predict the Virality of Vaccine Misinformation Narratives?
Centers for Disease Control and Prevention - ERA accepted applications from nonprofits, colleges and universities, state and local governments and tribes. The notice adds further conditions, so read its eligibility section.
What is the deadline for Developing a Public Health Tool to Predict the Virality of Vaccine Misinformation Narratives?
Closed January 6, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $500,000 each. About $1.0 million in total for one award.
Who has won Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects grants before?
The largest recipients over five fiscal years were Unicef, National Foundation for the Centers for Disease Control & Prevention, Inc., Community Catalyst Inc. The program made 243 awards worth $857 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)